recent publications

• academic article

  • Good, C. W., Steinhubl, S. R., Brennan, D. M., Lincoff, A. M., Topol, E. J., Berger, P. B. Is there a clinically significant interaction between calcium channel antagonists and clopidogrel? Results from the clopidogrel for the reduction of events during observation (credo) trial Circulation-Cardiovascular Interventions  2012 5:77-81  DOI:10.1161/circinterventions.111.963405  PMID:22319066
  • Weber, M., Bhatt, D. L., Brennan, D. M., Hankey, G. J., Steinhubl, S. R., Johnston, S. C., Montalescot, G., Mak, K. H., Fox, K. A. A., Easton, D. J., Topol, E. J., Hamm, C. W., et al. High-sensitivity c-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: A substudy from the charisma trial Heart  2011 97:626-631  DOI:10.1136/hrt.2010.210419  PMID:21393433
  • Hankey, G. J., Hacke, W., Easton, J. D., Johnston, S. C., Mas, J. L., Brennan, D. M., Bhatt, D. L., Fox, K. A. A., Topol, E. J., Investigators, Charisma Trial Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients a prespecified substudy of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management and avoidance (charisma) trial Stroke  2010 41:1679-1683  DOI:10.1161/strokeaha.110.586727  PMID:20595658
  • Berger, P. B., Bhatt, D. L., Fuster, V., Steg, P. G., Fox, K. A. A., Shao, M. Y., Brennan, D. M., Hacke, W., Montalescot, G., Steinhubl, S. R., Topol, E. J., Investigators, Charisma Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease Circulation  2010 121:2575-2583  DOI:10.1161/circulationaha.109.895342  PMID:20516378
  • Dosh, K., Berger, P. B., Marso, S., van Lente, F., Brennan, D. M., Charnigo, R., Topol, E. J., Steinhubl, S. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention an analysis from the clopidogrel for the reduction of events during observation trial Circulation-Cardiovascular Interventions  2009 2:503-512  DOI:10.1161/circinterventions.109.879312  PMID:20031767
  • Steinhubl, S. R., Bhatt, D. L., Brennan, D. M., Montalescot, G., Hankey, G. J., Eikelboom, J. W., Berger, P. B., Topol, E. J., Investigators, Charisma Aspirin to prevent cardiovascular disease: The association of aspirin dose and clopidogrel with thrombosis and bleeding Annals of Internal Medicine  2009 150:379-386  DOI:10.7326/0003-4819-150-6-200903170-00006  PMID:19293071
  • Aronow, H. D., Steinhubl, S. R., Brennan, D. M., Berger, P. B., Topol, E. J., Investigators, Credo Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the clopidogrel for the reduction of events during observation (credo) trial American Heart Journal  2009 157:369-374  DOI:10.1016/j.ahj.2008.09.011  PMID:19185647
  • Best, P. J. M., Steinhubl, S. R., Berger, P. B., Dasgupta, A., Brennan, D. M., Szczech, L. A., Califf, R. M., Topol, E. J., Investigators, Credo The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the clopidogrel for the reduction of events during observation (credo) trial American Heart Journal  2008 155:687-693  DOI:10.1016/j.ahj.2007.10.046  PMID:18371477
  • Bhattacharyya, T., Nicholls, S. J., Topol, E. J., Zhang, R. L., Yang, X., Schmitt, D., Fu, X. M., Shao, M. Y., Brennan, D. M., Ellis, S. G., Brennan, M. L., Allayee, H., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk JAMA-Journal of the American Medical Association  2008 299:1265-1276  DOI:10.1001/jama.299.11.1265  PMID:18349088  PMCID:PMC3014051
  • Wang, T. H., Bhatt, D. L., Fox, K. A. A., Steinhubl, S. R., Brennan, D. M., Hacke, W., Mak, K. H., Pearson, T. A., Boden, W. E., Steg, P. G., Flather, M. D., Montalescot, G., et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the charisma trial European Heart Journal  2007 28:2200-2207  DOI:10.1093/eurheartj/ehm274  PMID:17673448
  • Saw, J., Brennan, D. M., Steinhubl, S. R., Bhatt, D. L., Mak, K. H., Fox, K., Topol, E. J., Investigators, Charisma Lack of evidence of a clopidogrel-statin interaction in the charisma trial Journal of the American College of Cardiology  2007 50:291-295  DOI:10.1016/j.jacc.2007.01.097  PMID:17659194
  • Shishehbor, M. H., Zhang, R. L., Medina, H., Brennan, M. L., Brennan, D. M., Ellis, S. G., Topol, E. J., Hazen, S. L. Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease Free Radical Biology and Medicine  2006 41:1678-1683  DOI:10.1016/j.freeradbiomed.2006.09.001  PMID:17145556  PMCID:PMC1945055
  • Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., Flather, M. D., Haffner, S. M., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events New England Journal of Medicine  2006 354:1706-1717  DOI:10.1056/NEJMoa060989  PMID:16531616
  • Mukherjee, D., Topol, E. J., Moliterno, D. J., Brennan, D. M., Ziada, K., Cho, L., Steinhubl, S. R., Investigators, Credo Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment Heart  2006 92:49-51  DOI:10.1136/hrt.2005.064501  PMID:15845611  PMCID:PMC1860989
  • Gurm, H. S., Lincoff, A. M., Kleiman, N. S., Kereiakes, D. J., Tcheng, J. E., Aronow, H. D., Askari, A. T., Brennan, D. M., Topol, E. J. Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions American Journal of Cardiology  2004 94:30-34  DOI:10.1016/j.amjcard.2004.03.025  PMID:15219504
  • Merlini, P. A., Rossi, M., Menozzi, A., Buratti, S., Brennan, D. M., Moliterno, D. J., Topol, E. J., Ardissino, D. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting Circulation  2004 109:2203-2206  DOI:10.1161/01.cir.0000127867.41621.85  PMID:15117843
  • Aronow, H. D., Novaro, G. M., Lauer, M. S., Brennan, D. M., Lincoff, A. M., Topol, E. J., Kereiakes, D. J., Nissen, S. E. In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization - a propensity analysis Archives of Internal Medicine  2003 163:2576-2582  DOI:10.1001/archinte.163.21.2576  PMID:14638557
  • Roffi, M., Mukherjee, D., Chew, D. P., Bhatt, D. L., Cho, L., Robbins, M. A., Ziada, K. M., Brennan, D. M., Ellis, S. G., Topol, E. J. Lack of benefit from intravenous platelet glycoprotein iib/iiia receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts - a pooled analysis of five randomized clinical trials Circulation  2002 106:3063-3067  DOI:10.1161/01.cir.0000041250.89627.a9  PMID:12473552
  • Gurm, H. S., Brennan, D. M., Booth, J., Tcheng, J. E., Lincoff, A. M., Topol, E. J. Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox) American Journal of Cardiology  2002 90:42-5  DOI:10.1016/s0002-9149(02)02384-6  PMID:12088778